HER2-POSITIVE BREAST CANCER

This study is testing whether a personalized treatment approach can lead to long-term remission or cure for people with advanced HER2-positive breast cancer. Researchers will use regular blood tests to guide treatment decisions, adjusting therapies based on cancer activity while …

This trial is testing whether the drug trastuzumab-deruxtecan (T-DXd) can cure HER2-positive breast cancer that has spread to only 1-3 distant sites in the body. It will enroll 72 patients who have not received prior treatment for this spread. The goal is to use the drug before a…

This study is testing whether a combination of two drugs, trastuzumab deruxtecan and durvalumab, can shrink tumors before surgery in people with stage III inflammatory breast cancer that expresses the HER2 protein. The goal is to see if this treatment can eliminate all detectable…

This study is testing whether a new drug called BL-M07D1, given with or without pertuzumab, works better than standard chemotherapy before surgery for HER2-positive breast cancer. The trial will involve 120 women with stage 2 or 3 breast cancer who haven't had previous cancer tre…

This study is observing how well the drug trastuzumab-rezetecan works and how safe it is for people with HER2-positive or HER2-low breast cancer in real-world medical settings. It will follow 300 patients who are already scheduled to receive this treatment as part of their regula…

This study is testing whether adding an experimental drug called zanidatamab to standard chemotherapy helps eliminate HER2-positive breast cancer before surgery. Researchers will enroll 125 people with early-stage breast cancer to see if this combination leads to better outcomes.…

This study aims to understand how well the drug trastuzumab deruxtecan works and what side effects patients experience in real-world medical settings in China. It will follow 800 adults with advanced breast cancer that has spread and is difficult to remove surgically. Researchers…

This study is testing whether a combination of two targeted drugs (pertuzumab and trastuzumab) plus hormone therapy, given after surgery, can help prevent cancer from returning in people with early-stage, hormone-positive, HER2-positive breast cancer. About 375 participants will …

This study is testing a new type of treatment called CAR-NK cell therapy for people with advanced breast cancer that has stopped responding to standard treatments. Doctors will collect a patient's own natural immune cells, modify them in a lab to better recognize and attack cance…

This study compares two different drug combinations to see which works better at preventing breast cancer from coming back after initial treatment. It's for women with a specific type of breast cancer (HER2-positive) who still have a small amount of cancer after their first round…

This study is testing whether adding a personalized vaccine to standard chemotherapy and targeted drugs can better treat HER2-positive breast cancer before surgery. The vaccine is made from the patient's own immune cells and aims to train the body to attack the cancer. Researcher…

This study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…

This study is testing whether a newer targeted drug combination (T-DM1 followed by Herceptin Hylecta) causes fewer side effects than the standard treatment (paclitaxel with Herceptin Hylecta) for people with early-stage HER2-positive breast cancer after surgery. About 500 partici…

This study is for people with a specific type of breast cancer (HER2-positive) that has spread to only a few other places in the body. Researchers want to know if adding surgery or targeted radiation to the standard drug treatment helps keep the cancer under control for longer co…

This study is testing a combination of three drugs given to patients before breast cancer surgery. The goal is to see if this treatment can shrink tumors and potentially eliminate all detectable cancer by the time of surgery. It is for postmenopausal women with a specific type of…

This is an early-stage study to find a safe and effective dose of a new drug called IAM1363 for people with advanced cancers that have specific changes in a protein called HER2. The trial will enroll about 243 adults whose cancer has worsened after standard treatments, including …

This early-stage study is testing the safety of a new combination treatment for people with metastatic HER2-positive breast cancer. It uses a personalized vaccine to train the immune system, followed by an infusion of specially grown immune cells, alongside standard medications. …

This study is for people with advanced HER2-positive breast cancer that cannot be removed by surgery. It aims to see if a new drug called IBI354, given with or without another drug (pertuzumab), works better and is safer than the current standard first treatment. About 540 partic…

This study is testing whether radiation therapy followed by targeted cancer drugs delivered directly into the spinal fluid is safe and effective for treating HER2-positive breast cancer that has spread to the lining of the brain and spinal cord. The trial will involve 39 patients…

This study is testing whether a combination of targeted radiation to the brain and/or spine, followed by a three-drug therapy, is safe and effective for people with an aggressive form of advanced breast cancer that has spread to the fluid surrounding the brain and spinal cord. It…

This study is testing if a blood pressure drug called nebivolol can protect the heart from damage caused by trastuzumab, a life-saving breast cancer treatment. It will involve 56 women with HER2-positive breast cancer who are starting trastuzumab therapy. Researchers will measure…

This trial aims to find the best drug combinations for different types of breast cancer before surgery. It tests new drugs alongside standard chemotherapy in 5,000 women with early-stage or locally advanced breast cancer. The study uses tumor analysis and MRI scans to match treat…

This is a first-in-human safety study testing a new immune-boosting vaccine for breast cancer that has spread to the membranes surrounding the brain and spinal cord. Researchers will give the vaccine directly into the spinal fluid of up to 18 patients to find the highest dose tha…

This study is testing a targeted cancer treatment approach for Nigerian women with HER2-positive breast cancer. Participants receive a combination of targeted drugs and chemotherapy both before and after surgery. The research aims to see how effective and safe this treatment is f…

This is an early-stage study testing a new vaccine designed to teach the body's immune system to recognize and attack HER2-positive breast cancer cells. It is for people with high-risk, locally advanced breast cancer who have already completed standard HER2-targeted therapy. The …

This large study is testing whether a new drug called BL-M07D1 works better than the current standard treatment (T-DM1) for people with a specific type of breast cancer. It's for women with HER2-positive breast cancer who still have some cancer cells left after their initial chem…

This study is testing whether a new drug called TQB2102 works better than the current standard treatment for shrinking HER2-positive breast cancer tumors before surgery. It will involve 544 patients with early-stage breast cancer who haven't had prior cancer treatment. The main g…

This early-stage study is testing the safety and effectiveness of combining two drugs, palbociclib and avelumab, for patients with advanced breast cancer. It focuses on a specific, hard-to-treat type called AR-positive triple-negative breast cancer. The goal is to see if this new…

This study is testing whether a diagnostic tool called HER2DX can help doctors choose the best treatment for people with early-stage HER2-positive breast cancer. About 304 participants will be randomly assigned to receive either standard treatment or treatment guided by the HER2D…

This study is testing whether a special full-body MRI scan can find breast cancer that has returned or spread to other parts of the body earlier than current methods. It will enroll 145 women with high-risk forms of breast cancer (HER2-positive or Triple Negative) who have finish…

This study is testing whether regular MRI brain scans can help find breast cancer that has spread to the brain earlier than usual. It involves patients with certain aggressive or metastatic breast cancer types where brain screening is not currently standard. The goal is to see if…

This study is testing if a special type of mammogram that uses a contrast dye can work as well as a breast MRI to see if chemotherapy successfully shrank a breast tumor before surgery. It involves about 30 people with locally advanced breast cancer who are getting chemotherapy be…

This study is testing whether probiotic supplements can help prevent severe diarrhea in people with HER2-positive breast cancer who are taking the drug neratinib. About 308 participants will be randomly assigned to take either probiotics or a placebo, while all will also receive …

This study aims to learn if a blood test that looks for tiny pieces of tumor DNA can predict how well chemotherapy works for breast cancer patients. It will observe 125 women with stage II or III breast cancer who are receiving chemotherapy before surgery. Researchers will track …

This study collects real-world information from 60 Russian breast cancer patients who have already received trastuzumab deruxtecan treatment. Researchers will review medical records to understand how well the drug works in everyday clinical practice. The goal is to learn about tr…

This study aims to find out if regular brain MRI scans can detect cancer that has spread to the brain in patients with advanced breast cancer who have no neurological symptoms. Researchers will enroll 170 patients with stage IV breast cancer to see how often these scans find hidd…

This study is testing whether a new optical scanning device called NearWave can monitor how breast cancer responds to chemotherapy before surgery. Researchers will use the device on 15 patients receiving chemotherapy to see if it collects good enough data to predict treatment suc…